Bristol Myers’ lead deal negotiator to depart after inking series of multibillion-dollar acquisitions
Elizabeth Mily, the lead acquisition and deal negotiator at Bristol Myers Squibb, is leaving the Big Pharma, a spokesperson confirmed to Endpoints News on Friday morning.
Since joining Bristol Myers in the spring of 2020 as EVP of strategy and business development, Mily had helped orchestrate a trio of multibillion-dollar acquisitions, two of which have beefed up the pharma giant’s oncology portfolio and another that has spurred its push in cardiovascular diseases.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.